Opendata, web and dolomites

FGFSTAB

Industrial Production of Stable Fibroblast Growth Factors for Regenerative Medicine and Related Research Areas

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FGFSTAB project word cloud

Explore the words cloud of the FGFSTAB project. It provides you a very rough idea of what is the project "FGFSTAB" about.

fact    play    adverse    primarily    clinical    incidences    innovative    half    cleared    rising    marketing    industrial    slow    obesity    regenerative    stress    additional    world    care    investing    proteins    population    fgf    goes    course    despite    healing    platform    stable    biotechnological    heavily    greatest    organisms    demanding    started    commercial    sme    companies    fibroblast    circulation    skin    global    safe    fireprot    proprietary    frequent    protein    optimization    diabetes    authorization    trauma    technological    fgfs    surgical    angiogenesis    chronic    fgfstab    homeostasis    medicine    lower    natural    dressings    ulcers    enantis    thermal    stability    effectiveness    treatment    market    engineering    see    close    good    poor    gap    expertise    limited    aging    life    hours    body    minutes    ageing    trials    instrument    financial    risk    therapy    administrations    closes    embryonic    manufacturing    wound    practise    necessitating    tissue   

Project "FGFSTAB" data sheet

The following table provides information about the project.

Coordinator
ENANTIS SRO 

Organization address
address: KAMENICE 771/34
city: BRNO
postcode: 625 00
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Czech Republic [CZ]
 Project website https://www.enantis.com/fgfstab/
 Total cost 1˙030˙000 €
 EC max contribution 1˙030˙000 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ENANTIS SRO CZ (BRNO) coordinator 1˙030˙000.00

Map

 Project objective

The FGFSTAB project closes the gap between Enantis knowledge and expertise on protein engineering and the commercial applications of stable fibroblast growth factors (FGFs). FGFs are essential to the embryonic development, maintain tissue homeostasis, may slow down ageing of the organisms, and primarily promote angiogenesis and wound healing. FGFs see the greatest application in the care and treatment of chronic skin ulcers, but find use also in surgical and trauma wound healing. The global wound care market is rapidly growing due to the rising aging population and growing incidences of obesity and diabetes. Advanced wound dressings, such as those involving growth factors, play an important role in current regenerative medicine and companies around the world have started investing heavily in research and development of growth factor-based products. However, despite clinical value, applications of FGFs are limited by the fact that natural proteins have poor thermal stability and a short half-life in the circulation; they are often cleared from the body within hours, if not minutes, thus necessitating frequent administrations during the course of treatment, which goes hand in hand with a higher risk of adverse effects and lower cost-effectiveness of the protein therapy. The key objective of the FGFSTAB project is to use an innovative technological platform, based on the application of Enantis proprietary protein optimization concept FireProt, to increase FGF stability under various stress conditions. Additional challenges including high cost of production, current Good Manufacturing Practise, development of delivery systems for safe and effective wound healing, and pre-clinical testing to support future clinical trials and marketing authorization, will be targeted as well. Financial support provided within SME Instrument phase 2 will help us to close the gap from demanding biotechnological development to the target industrial application in regenerative medicine.

 Deliverables

List of deliverables.
FGFSTAB web presentation Websites, patent fillings, videos etc. 2019-09-09 15:23:38

Take a look to the deliverables list in detail:  detailed list of FGFSTAB deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FGFSTAB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FGFSTAB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More